Ranbaxy Laboratories is currently trading at Rs. 496.80, up by 3.95 points or 0.80% from its previous closing of Rs. 492.85 on the BSE.
The scrip opened at Rs. 490.00 and has touched a high and low of Rs. 499.75 and Rs. 488.35 respectively. So far 28783 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 570.00 on 02-Aug-2011 and a 52 week low of Rs. 366.50 on 19-Dec-2011.
Last one week high and low of the scrip stood at Rs. 505.00 and Rs. 477.65 respectively. The current market cap of the company is Rs. 20900.90 crore.
The promoters holding in the company stood at 63.67% while Institutions and Non-Institutions held 20.47% and 13.82% respectively.
Ranbaxy Laboratories’ former flagship skincare brand Sotret will soon be re-launched in the US through Cipher Pharmaceuticals, a Canada based company. The final review of the drug will be conducted on May 29, 2012 by the US drug regulator - USFDA.
Sotret along with other 30 drugs were banned in September 2008 by the USFDA for violating US drug manufacturing norms. Prior to the ban, Sotret had generated approximately $50 million in annual sales and was Ranbaxy's third best selling drug globally.
Cipher is the marketing partner for Sotret which specializes in developing improved formulations of existing drugs out-licenses them to partners for a fee.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1808.20 |
| Dr. Reddys Lab | 1322.95 |
| Cipla | 1309.90 |
| Zydus Lifesciences | 891.65 |
| Lupin | 2303.70 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: